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ABSTRACT
Background: The impact of iron supplements and iron fortification on diarrhea in children is
controversial, with some studies reporting an increase and others reporting no effect.
Objective: The aim of the study was systematically assess the published literature on oral iron
supplementation and fortification to evaluate its impact on diarrhea incidence among children
aged 4–59 mo.
Methods: Randomized controlled trials of oral iron supplementation or iron fortification that
reported diarrheal outcomes in children aged 4–59 mo were identified from a systematic search
of 5 databases.
Results: Of the 906 records identified, 19 studies were found to fit the inclusion criteria for this
systematic review. However, variable case definitions for diarrhea made meta-analysis impossible.
Of the 19 studies, 7 (37%) studies showed a significant increase, either in overall diarrhea
incidence or within a specific subgroup of the population, between iron-supplemented and
control groups. Subgroups included children who were iron-replete and children undergoing
their first month of iron intervention. Two studies reported an increase in bloody diarrhea. The
remaining 12 (63%) studies showed no difference between iron-supplemented and control
groups.
Conclusions: Studies on iron supplementation and fortification use divergent case definitions for
diarrhea. A number of studies (37%) showed an increase in overall diarrhea incidence or within a
specific subgroup of the population, between iron-supplemented and control groups, but the
majority (63%) did not. In addition, there was no clear relation between diarrhea and type of
intervention or amount of iron administered observed. In future studies, we recommend that
diarrhea be clearly defined and consistently recorded as a secondary outcome. Antibiotic status
of participants receiving iron should also be collected to help assess possible drug interactions
resulting in a “red stool effect.” Finally, further microbiome research is required to better
understand the effects of oral iron on specific bacterial species in the colon. Curr Dev Nutr
2019;3:nzz005.
Introduction
Iron is required for many essential metabolic processes (1). Pathogens and humans require iron
and have developed complex ways to acquire, transport, and store it (2). Bacteria have developed
multiple mechanisms for chelating iron and heme directly and for acquiring iron attached to
various human iron chaperone molecules (3). In turn, humans tightly regulate free iron at a
molar concentration of less than 1024, and bind it with proteins such as ferritin, transferrin, and
lactoferrin (4).
Iron deficiency anemia occurs when both intake and total body iron are insufficient to meet
the needs of erythropoiesis. A 2011 WHO report estimated a prevalence of 43% of anemia
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worldwide (5), with over half of cases attributable to iron deficiency (6).
Infants aged 0–5 y, pregnant women, andwomen of childbearing age are
at highest risk (7). Relative iron requirements for children are higher
than adults because of the nutritional demands of accelerated growth
(8). Among its many uses, iron is essential for brain growth: it is neces-
sary for myelination of oligodendrocytes (9) as well as the production
of the key neurotransmitters serotonin (10) and dopamine (11).
In low-income countries, there is concern that untargeted iron sup-
plementation can predispose children to certain infections, including
malaria, diarrhea, and respiratory infections. One previous systematic
review published in 2002 analyzed 28 randomized controlled trials (no
age limits on participants) for the effect of both iron supplementation
(oral and parenteral) and fortification on a number of infectious disease
outcomes (12). In the analysis, subjects receiving iron had a higher risk
of only 1 complication, diarrhea (at an 11% increase).
Iron supplementation and fortification could induce diarrhea by
causing intestinal damage through oxidative stress (13–16) or by
initiating bacterial dysibiosis and gut inflammation (17–20).
This review focuses specifically on children from the ages of 4 mo to
5 y, a population group that is concurrently at the highest risk of diarrhea
and most likely to benefit from iron intervention (8, 21). The primary
objective is to systematically assess the published literature on oral iron
supplementation and fortification to evaluate its impact on diarrhea
incidence among children aged 4–59 mo. Secondary objectives include
establishing whether any specific population subgroups are at increased
risk of diarrhea and discussing possible potential policy implications
based on the results found.
Methods
Search strategy
This systematic review adheres to the Preferred Reporting Items
for Systematic Review and Meta-Analysis (PRISMA) 2009 Checklist
(Supplemental Table 1) (22). We published the protocol for this study
on 19May 2017 (CRD42017067297).We conducted a systematic search
across 5 different databases; Medline (1946 to July 2017), EMBASE
(1974 to 2017 week 31), Global Health (1910 to 2017), Web of Science,
and Cochrane Central Register of Controlled Trials. The last search
was conducted on 31 July 2017. The search strategy consisted of 4
main concepts: “children,” iron,” “supplementation/fortification,” and
“diarrhea” (Supplemental Table 1). Owing to the similarity of Boolean
operators, Ovid was used to retrieve searches from 3 databases—
Medline, EMBASE, and Global Health—simultaneously. For studies
that were indexed by the search but inaccessible, relevant authors were
contacted to retrieve full texts. Through this method, 1 further full text
was made accessible (23).
Inclusion and exclusion criteria
We restricted the review to double-blind, randomized controlled trials
in humans. Searches were limited to the English language. Inclusion
criteria were predefined in the published protocol and are reported in
the Cochrane endorsed population intervention comparator outcome
format (24): population—children between the ages of 4 mo and
5 y at the initiation of iron intervention; intervention—oral iron
supplementation or fortification of any kind, any dose and any
duration, includingmultiple micronutrient supplementation if iron was
a principal component; comparator—any placebo or control group
of the same population receiving no intervention or an intervention
containing negligible amounts of additional iron; outcome—diarrhea or
dysentery cases reported as either a primary or secondary outcome in
any format. We excluded review articles, case studies, and unpublished
trials. Studies that obtained participants with existing cases of diarrhea
were excluded because they were unrepresentative of the general
population. Nonoral iron supplementation, formulated foods, lipid-
nutrient supplementation, meat-based iron supplementation, infant
formula milk, fortified breast-milk, and bovine lactoferrin were all
excluded.Owing to existing evidence that zinc supplementation reduces
risk of diarrhea (25, 26), we excluded trials that combined the iron
and zinc supplementation arm, unless there was also an iron-only arm.
Owing to frequent inconsistencies in the case definitions for diarrhea,
we included all case definitions of diarrhea as described in the studies.
Analysis
Owing to substantial heterogeneity of reported outcomes, it was not
possible to conduct a meta-analysis, and instead a vote-counting
method was used. Studies were classified as either increasing risk of
diarrhea with iron formulation/supplementation or having no effect
using a significance level of P < 0.05. We described the overall trend
of the studies, with a focus on whether any population subgroups or
intervention types were particularly affected by iron supplementation
or fortification.
Risk of bias
All studies progressing to the extraction phase were assessed using the
Cochrane risk of bias tool to ensure adequate quality (27). Categories
assessed included: selection bias, detection bias, attrition bias, reporting
bias, and “other” biases (such as poor case definitions as well as weak
methods of outcome detection).
Every study was assessed for each category of bias individually,
and a judgment was made to score the bias as “low risk,” “high risk,”
or “unclear risk” if information was insufficient. The bias scores in
each category were then used to obtain an overall statement of study
quality. Studies were initially considered to be “high quality” and were
downgraded to “adequate quality” and “low quality” for each additional
category containing a high risk of bias. Studies that scored an “unclear”
risk in 4 or more categories were also downgraded in quality.
All studies progressing to the final stage of the review underwent
full data extraction regardless of risk of bias. Risk of bias data was
recorded and assessed using RevMan v5.2 to display quality outcomes
both within and between studies.
Results
Included studies
As detailed in Figure 1, a total of 906 records were identified using
the predefined search strategy (Supplemental Table 1). A total of 249
duplicates were removed, and of the remaining 657 studies, 143 were
eligible for full text appraisal. Four potentially relevant texts were
deemed inaccessible. Corresponding authors were contacted, and 1
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FIGURE 1 Study selection flow diagram. LNS, lipid-based nutrient supplement.
text was successfully retrieved (23). A full list of excluded studies with
reasons for exclusion is available in Supplemental Table 2.
Nineteen studies progressed to the final stage of review and ranged in
publication date from1991 to 2017. The papers summarized global data;
9/19 studieswere fromAsia (3 fromBangladesh, 2 fromPakistan, 2 from
China, 1 fromCambodia, 1 from India), 4 fromAfrica (3 fromKenya, 1
from South Africa), 4 from North America (Canada, Honduras, Haiti,
Mexico), 1 from South America (Peru), and 1 from Europe (Sweden).
One study, undertaken by Dewey et al. (28), included 2 simultaneous
cohorts from both Honduras and Sweden. As such, these cohorts have
been considered separately in the analyses.
Study design
All 19/19 studies were randomized controlled trials, with 7 being of a
simple design, containing a placebo and iron-intervention group only.
The remaining studies (12/19) included multiple intervention arms
(Tables 1 and 2). Only 2 studies did not randomly assign individual
participants: Menon et al. (29) and Soofi et al. (30), who used cluster
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randomization of villages and food distribution points respectively. The
total duration of intervention varied greatly, from 2 to 18 mo. One
study, Chen et al. (31), showed a modestly inflated study duration, as
the intervention was suspended during weekends and holidays, leading
to the reported length of 6 mo being equivalent to 120 supplementation
days (4 mo).
Population
Four out of 19 studies recruited their participants in a hospital
setting either through routine infant clinics or at birth, 13/19 studies
recruited frompredefined geographical areas, and 2/19 enrolled nursery
attendees. Eleven out of 19 studies selected children under the age of
12 mo, with 9 of these selecting children 6 mo old or older, as they
began complementary feeding. Two studies, Luabeya et al. (32) and
Lemaire et al. (33), recruited participants with existing comorbidities:
HIV infection and moderate acute malnutrition respectively. All other
studies detailed specific inclusion and exclusion criteria, excluding
participants with congenital malformations or chronic diseases (Sup-
plemental Table 3).
Intervention style
Nine out of 19 studies involved direct supplementation of iron through
the use of syrups, tablets, capsules, and solutions. Five studies involved
traditional fortification: 2 studies using maize, 1 study using wheat,
and 2 studies using a nondescript cereal for fortification. “Point of use
fortification,” often interchangeably termed “sprinkles,” “micronutrient
powders,” or “at-home fortification,” was used by 5 studies (Table 3).
Intervention type
Two studies, Menon et al. (29) and Chang et al. (34), did not
specify the type of iron used. The remaining studies used iron
sulfate, fumarate, gluconate, sulfate, or sodium iron ethylene diamine
tetraacetate (NaFeEDTA). One study, Paganini et al. (23), used a novel
combination of 2 forms of iron: ferrous fumarate andNaFeEDTA (Table
4).
Intervention frequency
All studies provided participants with a regime of daily iron supplemen-
tation, besides Chang et al. (34) who supplemented on alternate days
(Supplemental Table 4). Four out of 19 studies adjusted their iron dose
according to either weight or age, with the remainder using a fixed dose
of daily iron. Significant heterogeneity in amount of iron delivered was
seen between studies. A full list of detailed ingredients and intervention
types for each intervention is provided in Supplemental Table 5.
Outcome
Five out of 19 studies did not provide a specific case definition for the
diagnosis of diarrhea, with only 10 of 19 studies using the standard
definition of “three ormorewatery stools within a 24 hour period.” In all
studies, cases were reported by infants’mothers to a fieldworker or study
personnel via informal interviews or written questionnaires. One study,
Mitra et al. (35), deviated from this method by additionally including
physician’s records when measuring diarrhea incidence (Supplemental
Table 3).
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TABLE 3 Reported effect of intervention on diarrhea incidence by iron type1
Iron type Increased incidence No effect
Ferrous sulfate Dewey et al. (28) Richard et al. (72)
Ferrous sulfate Baqui et al. (36) Chen et al. (2013) (71)
Ferrous sulfate Rosado and Allen (73)
Ferrous gluconate Abdelrazik et al. (38)
Ferrous gluconate Mitra et al. (35)2
Ferrous fumarate Soofi et al. (30)2 Jaeggi et al. (17)
Ferrous fumarate Luabeya et al. (32)
Ferrous fumarate Lemaire et al. (33)
Ferrous fumarate Christofides et al. (62)
Ferrous fumarate Javaid et al. (69)
Ferrous fumarate Giovannini et al. (68)
NaFeEDTA + ferrous fumarate Paganini et al. (23)
NaFeEDTA Barth-Jaeggi et al. (67)
NaFeEDTA Chen et al. (2011) (31)
Nondescript iron Chang et al. (34)
Nondescript iron Menon et al. (29)2
1NaFeEDTA, sodium iron ethylene diamine tetraacetate.
2Significant increase within population subgroup only.
Effect of intervention
Twelve out of 19 (63%) studies showed no significant difference in
diarrheal outcomes between intervention and placebo groups. Four
out of 19 (21%) studies showed a significant difference in diarrhea
incidence between groups, with all reporting an increase in morbidity.
Reported outcome formats varied greatly with a variety of rates, ratios,
proportions, and raw numbers all being presented. A further 3 out
of 19 (16%) studies showed a higher rate of diarrhea in specific
subgroups only. Mitra et al. (35) demonstrated strong evidence of an
increased rate of dysentery (defined as mucus or blood-containing
stool) in children under 1 year of age. Menon et al. (29) reported a
significant increase in diarrheal incidence in iron-replete infants during
the initial month of supplementation. Soofi et al. (30) also presented
a strongly significant increase in bloody diarrhea within those taking
iron-containing micronutrient powders.
Although no formal statistical analyses were conducted, no clear
relation between style of supplementation and diarrheal incidence
was evident. Baqui et al. (36) showed no effect of 20 mg ferrous
sulfate supplementation alone but an increased incidence in diarrheal
morbidity when iron was delivered as a multiple micronutrient
formation. None of the 3 studies that used NaFeEDTA led to increases
in diarrheal incidence. There was also no clear relation between volume
of iron administered and diarrheal outcomes.
Risk of bias
The risk of bias assessment was determined on all 19 studies (Table 5
and Figure 2). The overall risk of bias was low, with 9/19 (47%) studies
considered “high” quality, a further 8/19 (42%) being of “adequate,” and
just 2/19 (11%) being considered “low” quality. Between studies, the
most common risk of bias was that of reporting bias with 6/19 (31%)
studies scoring inadequately in this area. For the majority of papers,
diarrhea was not a primary outcome and often only added as an aside
to the original results if deemed noteworthy.
TABLE 4 Reported effect of intervention on diarrhea incidence by intervention style1
Intervention
category Intervention form
Increased
incidence No effect
Fortification Cereal Chen et al. (2011) (31)
Cereal Javaid et al. (69)
Wheat soy blend Menon et al. (29)1
Maize Jaeggi et al. (17)
Maize Barth-Jaeggi et al. (67)
Point-of-use
fortification
Sprinkles Soofi et al. (30)1 Christofides et al. (62)
Sprinkles Lemaire et al. (33)
Sprinkles Paganini et al. (23)
Sprinkles Giovannini et al. (68)
Supplementation Syrup Abdelrazik et al. (38) Richard et al. (72)
Syrup Mitra et al. (35)1
Syrup Dewey et al. (28)
Tablet/capsule Baqui et al. (36) Luabeya et al. (32)
Tablet/capsule Chen et al. (2013) (71)
Dissolvable tablet/solution Chang et al. (34) Rosado and Allen (73)
1Significant increase within population subgroup only.
CURRENT DEVELOPMENTS IN NUTRITION
D
ow
nloaded from
 https://academ
ic.oup.com
/cdn/article-abstract/3/3/nzz005/5289571 by London School of H
ygiene & Tropical M
edicine user on 29 M
arch 2019
Guts, Germs, and Iron 9
TABLE 5 Risk of bias assessment for included studies1
(38)
(36)
(67)
(34)
(71)
(31)
(62)
(28)
(68)
(17)
(69)
(32)
(29)
(35)
(23)
(72)
(73)
(30)
(33)
1Green cells, low risk of bias; gray cells, unclear risk of bias; red cells, high risk of bias.
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FIGURE 2 Cochrane risk of bias graph for included studies.
All studies (19/19) reported random sequence generation, but 6/19
did not disclose their exact methods of randomization. Performance
bias was adequately addressed in 16/19 papers, with only Soofi et al.
(30) being downgraded to “high risk” because of a lack of use of an
adequate placebo. Papers with the lowest risk of bias in this category,
such as Jaeggi et al. (17), used triangle taste testing to ensure participants
could not discriminate between iron compounds and placebo. Blinding
of outcome assessors was described in 12/19 studies and unreported
in the remainder. Studies not reporting this bias category tended to be
older, predating the 2010 Consolidated Standards of Reporting Trials
(CONSORT) criteria (37). Seventeen out of 19 studies provided attrition
data, usually via an annotated flow diagram accounting for loss to
follow-up for each individual.
Six out of 19 studies were categorized as being at high risk of
reporting bias; this was mainly due to the incomplete presentation of
both absolute and relative values for diarrhea incidence. In many cases,
this was because diarrhea was not an intended primary outcome. One
study by Lemaire et al. (33) was suspected of reporting bias due to the
presentation of a composite outcome consisting of dysentery, diarrhea,
and lower respiratory tract infections as a single figure. In order to
account for this, supplementary data for this study were located to
retrieve outcome-specific results. When considering “other” sources of
bias, 3/19 studies were penalized for having weak or nondescript case
definitions. Supporting statements for each risk of bias judgment are
provided in Supplemental Table 6.
Discussion
In summary, of the 19 studies extracted, 12 showed no effect of iron
on diarrheal incidence, 4 showed a significant increase, and a further 3
showed an increase within a specific subpopulation.
Iron and pathogen-induced diarrhea
Iron supplement/fortificant-induced diarrhea could be due to 2 can-
didate mechanisms: first, through the production of reactive oxygen
species and second through bacterial dysibiosis.
Iron itself has the potential to produce copious reactive oxygen
species within the intestinal tract through both the Haber–Weiss
and Fenton reactions (14). This has the unintended side-effect of
causing intestinal damage through oxidative stress, thus precipitating
lipid peroxidation and inflammatory diarrhea (13). This mechanism
has been demonstrated in in vitro studies with enterocyte-like cells
exhibiting a degradation in epithelial integrity after iron exposure
(15, 16).
Two recent randomized controlled trials have shown that iron
intervention can alter the gut microbiome (17, 18). Specifically, both
studies observed a trend toward increase inE. coli aswell as a concurrent
decrease in Lactobacillaceae (19). Both studies also showed a significant
increase calprotectin within the intervention group, a biomarker for gut
inflammation.
Because there are multiple biologically plausible mechanisms by
which oral iron supplementation could cause diarrhea and conflicting
clinical data, we attempted to perform an analysis of the current
literature to assess the possibility that a causal relation exists.
Diarrhea in the iron-replete
Four cohorts, Abdelrazik et al. (38), Menon et al. (29), Dewey et al.
Sweden/Honduras (28), extracted in this review displayed a higher
incidence of diarrhea specifically in children who were iron-replete
as defined by the study. This review’s findings, that iron-replete
individuals may be more susceptible to iron-induced diarrhea, support
current WHO guidelines that recommend the use of iron fortificant or
supplements only in areas that have an anemia prevalence of 40% and
20% respectively (39, 40).
Bloody diarrhea
Two studies, by Soofi et al. (30) and Mitra et al. (35), showed a
significantly increased incidence of acute bloody diarrhea within those
who received iron interventions. Acute bloody diarrhea, commonly
referred to as dysentery, is a symptom commonly associated with toxin-
producing bacteria such as Shigella, E. coli, Salmonella, or Campylobac-
ter (41). The results presented by the Pakistan study were alarming
enough to prompt a correspondence in The Lancet in 2013 with Tobe-
Gai et al., who called for an “urgent need… (for) robust evidence on age-
specific doses” of micronutrient powder (42). Although it is tempting to
attribute the results to iron administration, 1 further possibility is that
of antibiotic interactions. Unlike other cohorts, such as those in Jaeggi
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et al. (17) and Paganini et al. (23), the Pakistan study included
participants receiving antibiotic treatments at baseline. A candidate
antibiotic that may be accountable for the significant difference in
dysenteric outcomes is Cefdinir (43). Cefdinir is a third-generation
cephalosporin often used in pediatric populations for the treatment
of penicillin-resistant infections such as otitis media, sinusitis, and
pharyngitis (44–46) These infections are extremely common in infants
and also have an increasingly high resistance to first-line antibioticswith
recent reports estimating between 30% and 70% resistance (47). One
side-effect of Cefdinir that is becoming increasingly well documented
is its ability to cause the formation of red stools, especially when
coadministered with iron (48). Based on case reports, the volume
of iron needed to form these red-iron complexes is relatively low
(49). One small randomized controlled trial described the frequency
of stool discoloration from Cefdinir to be as high as 10%, with a
concurrent significant increase in diarrhea at higher doses (50). This
relatively commonCefdinir side-effect may falsely promote an apparent
association between iron administration and bloody diarrhea.
It is plausible that, especially in a sample of almost 3000 infants, a
plethora of antibiotics were prescribed, dependent on availability and
prescribing patterns of the region. It could be argued that both the
Pakistan cohort and theMitra et al. (35) Bangladesh cohort did not show
an increase in bloody diarrhea for all children, but only those younger
than 18 mo. If cephalosporin administration was accountable for this
relation, differential prescribing between age groups would have to be
demonstrated. Alternatively the association could be explained by the
epidemiology of otitis media itself, which has a peak incidence during
the first year of life, specifically 6–18 mo (51). During this period, we
would expect the prescription of cephalosporins to be most frequent
and thus the incidence of reported bloody diarrhea to be higher, as is
the case with both studies. Although unlikely, if antibiotic prescription
were liable for some of the results observed, the ramifications of these
findings would be significant.
Risk of diarrhea by type of intervention
Five out of 9 iron supplementation studies showed a significant increase
in the diarrhea. There is little consensus on which iron type should
be used. However, ferrous fumarate provides the most iron per gram,
ferrous sulfate is the cheapest, and ferrous gluconate is known for its
minimal side-effect profile (52). Fourteen studies utilized conventional
iron salts as a form of iron intervention. These include ferrous
fumarate, ferrous sulfate, and ferrous gluconate, in order of decreasing
bioavailability (53).
Three studies utilized NaFeEDTA, with all of these studies showing
no effect on diarrheal morbidity. The benefits of NaFeEDTA are 3-
fold. First, within the lumen of the intestine, the unconventional
manner in which the EDTA complex binds iron may sequester iron
from iron-dependent pathogens, thus withholding iron desperately
needed for survival (17). Second, it is well established through in vitro
experimentation that EDTA itself exhibits antimicrobial properties and
is commonly used to prevent the formation of biofilm. Recent studies
have pertinently shown that EDTA can induce the deterioration of
both E. coli and Salmonella enterica cell membranes (54, 55). Finally,
when used as a fortificant, the EDTA component also protects iron
from the inhibitory effect of phytates and polyphenols (56). Moreover,
NaFeEDTA has been reported to be absorbed 2–4 timesmore efficiently
than ferrous sulfate, the compound once considered the benchmark of
iron bioavailability (57, 58). Its use has been recently endorsed by the
WHO/FAOExpert Committee on FoodAdditives and is recommended
for use specifically with corn and condiments (56). Despite its inherent
benefits, NaFeEDTA is expensive, its effective cost per milligram
reported to be 16 times that of ferrous sulfate alone, making it less viable
for resource-poor programs (59).
Fortification is often considered as a safer alternative to supple-
mentation because of its smaller dose and a more physiological uptake
when combined with foods (58). This safety is somewhat represented
in our results, with only 1/5 “traditional” fortification studies and 2/5
sprinkle studies leading to an increased incidence of diarrhea [Table 4].
Although it appears that, when compared to fortificants, supplements
have a higher risk of diarrheal morbidity, it is important to note that
the data on the effectiveness of each intervention were not extracted.
For example, a study providing low-dose iron fortification may have
no effect on morbidity but also no effect on the intended outcome of
interest; usually serum ferritin. This limitation of this review makes it
difficult to recommend a specific form of intervention.
Limitations
The search term “iron” was an essential keyword in the search strategy
used. It is possible that a select few multiple micronutrient studies
would not have included the keyword “iron,” as it may have been an
assumed “micronutrient” in the collective whole. This constraint was
unavoidable if all iron interventions were to be captured, and a number
of reviews already exist that assess the safety of multiple micronutrient
interventions (60).
“Conventional vote-counting” (61) was themethod used to describe
the results of this review. This involves counting the number of trials
that showed an adverse effect of the intervention on diarrhea (7/19),
those that had a protective effect (0/19) and those that had no effect
(12/19). A great deal of literature has been published on vote counting
and its inherent flaws, which this study is also fallible to (62, 63).
In order to mitigate these effects, this review only “counted” positive
associations that were statistically significant at a significance level
of P < 0.05, whether that be in a specific subgroup or overall. This
adaptation provides a more robust overview of relations than older
forms of conventional vote-counting that often use a baseline cutoff of
P< 0.5 (64).
There was significant heterogeneity in how diarrheal outcomes were
reported. Proportions, risk ratios, incidence rates, and raw numbers
were all variously reported. However, “incidence” definitions varied,
with some studies reporting total frequency of diarrheal episodes
and others reporting the number of children who ever suffered from
diarrhea within a given period. The latter value always gives a number
below that of the total study population (n), whereas the former could
be much higher, as it accounts for children who suffer from multiple
discrete episodes of diarrhea throughout the study duration.
Conclusions
Undoubtedly there is a strong need for effective treatments for iron
deficiency. However, a delicate balance between providing iron to host
and increasing pathogen growth needs to be maintained, particularly
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in the gut. Factors such as genetics, gut integrity, diet, hygiene, and
inflammation status all contribute to the complex interplay between
iron and the gut (65, 66).
We recommend that future iron-intervention studies consider 3
key recommendations. First, diarrhea as defined by the WHO should
be recorded as a clearly reported secondary outcome, preferably as a
crude number. Second, antibiotic status of individuals enrolled in an
iron study should be collected, with those taking antibiotics at baseline
excluded. This would help account for possible drug interactions and
the possibility of the “red stool effect.” Finally, fecal bacteria should be
analyzed where possible to help contribute to the burgeoning field of
microbiome research and to further understand the selective effects of
iron on specific bacterial species. We hope that these recommendations
are modest yet sufficiently achievable to ensure that diarrhea is
adequately assessed in iron-intervention studies.
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